Company Description
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.
It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment.
In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson’s disease.
Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Timothy Warbington |
Contact Details
Address: 211 East Osborn Road Phoenix, Arizona 85012 United States | |
| Phone | 480 399 2822 |
| Website | creativemedicaltechnology.com |
Stock Details
| Ticker Symbol | CELZ |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1187953 |
| CUSIP Number | 22529Y408 |
| ISIN Number | US22529Y4089 |
| Employer ID | 87-0622284 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Timothy Warbington | Co-Founder, Chairman, President and Chief Executive Officer |
| Donald F. Dickerson MBA | Senior Vice President, Chief Financial Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2026 | 8-K | Current Report |
| Jul 1, 2026 | PRE 14A | Other preliminary proxy statements |
| Jun 30, 2026 | RW | Filing |
| Jun 26, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 25, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 28, 2026 | DRS | [Cover] Draft Registration Statement |
| May 8, 2026 | 10-Q | Quarterly Report |
| Apr 24, 2026 | 10-K/A | [Amend] Annual report |
| Mar 20, 2026 | 10-K | Annual Report |
| Dec 31, 2025 | 8-K | Current Report |